UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2022

Biomea Fusion, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation)

001-40335 (Commission File Number)

900 Middlefield Road, 4th Floor Redwood City, CA (Address of Principal Executive Offices)

82-2520134 (IRS Employer Identification No.)

> 94063 (Zip Code)

Registrant's Telephone Number, Including Area Code: (650) 980-9099

650 Main Street

Redwood City, CA 94063 (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Dere-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	Name of each exchange
Title of each class	Symbol(s)	on which registered
Common Stock, \$0.0001 par value	BMEA	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

Biomea Fusion, Inc. (the "Company") from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. On January 12, 2022, the Company will present an updated corporate presentation virtually at the 40th Annual J.P. Morgan Healthcare Conference and post the presentation in the "Investors & Media" portion of its website at *www.biomeafusion.com*. A copy of the Company's current corporate slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

The information contained in Item 7.01 of this Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

1

Item 9.01. Financial Statements and Exhibits.

Description

(d) Exhibits

Exhibit Number

- 99.1 Corporate Slide Presentation of Biomea Fusion, Inc. dated January 2022
- 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BIOMEA FUSION, INC.

Date: January 12, 2022

By: /s/ Thomas Butler Thomas Butler Principal Executive Officer

2



Corporate Presentation January 2022

Disclaimer and Forward-Looking Statement

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future business and financial performance of Biomea Fusion, Inc. (the "Company") and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. All statements other than statements of historical fact could be deemed forward-looking, including any projections of financial information or profitability, the initiation, timing and results of pending or future preclinical studies and clinical trials, the actual or potential actions of the FDA, the status and timing of ongoing research, development and corporate partnering activities, any statements about historical results that may suggest trends for the Company's business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, potential markets or market size, or technology developments, and other factors affecting the Company's financial condition or operations. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors may cause actual results, performance or achievements as different statements. The factors may cause actual results are only predictions and involve known and unknown risks and assumptions. The statement is a statement of the statemen to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company's expectations. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.







Biomea Fusion is a clinical-stage biopharmaceutical company focused on the discovery and development of irreversible small-molecule drugs to treat patients with genetically defined cancers. We believe that our approach may lead to significant improvement and extension of life for patients. Our team is engaged in all phases of drug discovery and development, including target selection, small molecule design, and preclinical and clinical studies to develop innovative medicines.



BMF-219 - Novel Irreversible Covalent Inhibitor of Menin

Pipeline-in-a-Pill – Single Agent for Multiple Indications



Strong Pathway Control

Large effect on target genes and proteins leading to cell death



Multiple Shots on Goal

Acute leukemias, MYC addicted and driven cancers, RAS/RAF driven solid tumors



Consistent On-Target Effect

Pathway control and cell killing seen at same predicted dose across indications



Wide Safety Margin Strong preclinical safety profile from animal studies



Our Team – 10+ Years of Success Together















Thomas ButlerRamses ErdtmannChairman & CEOPresident & COO

Franco Valle **Chief Financial** Officer

Naomi Cretcher Chief of People

Heow Tan Quality Officer

Chief Technical & Chief Medical Officer Consultant

Steve Morris MD Thorsten Kirschberg EVP of Chemistry

Jim Palmer VP of Drug Discovery

 15+ years in Life Science
 15+ years in Life Science

 Pharmacyclics
 Pharmacyclics

 Gilead Sciences
 Oxygen Investments

 UCLA - MBA Finance
 University of Münster,

 Master's in Banking & Corp Finance
 Corp Finance

 15+ years in Life Science
 15+ years in Life Science

 Eidos Therapeutics
 Pharmacyclics

 Iovance Biotherapeutics
 Genentech

 Pharmacyclics
 UC Irvine, BA Comm

 CalidusCloud
 SF State University, Comm
 PricewaterhouseCoopers San Jose State University, BS Corporate Finance

22+ years in Life Science 22+ years in Life Science Pharmacyclics Collegium Pharmaceutical Praecis Pharmaceuticals Ohio State University Santa Clara University Leavey School of Business, MBA – Finance & Mgmt

25+ years in Life Science HealthChart LLC Insight Genetics St. Jude Children's Research Hospital Board certified internist (Univ. of Texas SW HSC) and medical oncologist (Yale University School of Medicine) Ph.D., Chemistry




30+ years in Life Science Biota Ltd Cytopia Ltd. Rigel, Inc. Celera Genomics Prototek Inc. Purdue University Ph.D. Organic Chemistry



Our Vision – We Are Patient Focused and Aim to Cure

Biomea leverages the FUSION™ Platform to create a suite of novel agents to improve and extend life for patients



Validated Disease Targets

Drugs pursuing validated targets have a ~2x higher likelihood of approval than molecules pursuing a new mechanism of action

Sources: Nelson et al. (2015) Not Genet: Thomas et al. (2016) BIO; In a Landscape of 'Me Too' Drug Development, What Spurs Radical Innovation? HBS Weekly Review (Jun 2018)




Irreversible covalent inhibitors provide deep target inactivation and a wider therapeutic window, allowing for longer duration on therapy Sources: Singh et al. (2011) Nature Reviews Drug Discovery: Cheng et al. (2020) Journal of Hematalogy & Oncology. Strokov (2017) Stab Discovery: Roligitaria & Dahle et al. (2020) Journal of Hematalogy & Oncology.

Proprietary Combinations Combination therapy with non-overlapping resistance mechanisms results in more durable responses and better outcomes Sources: Paimer et al. (2019) etile: Mokhari et al. (2017) Oncotarget



Irreversible Inhibitors Have a History of Medical Success



- Aspirin was the first commercialized irreversible drug
- Notable precision oncology and infectious disease programs leverage irreversible mechanisms
 - Precision Oncology: Osimertinib and Ibrutinib both target kinases and are used in subpopulations with specific genetic biomarkers
 - Antivirals: **Sofosbuvir** and **Tenofovir** both target reverse transcriptases and are leveraged to treat HCV and HIV



Important Attributes of Irreversible Small Molecule Inhibition



High Selectivity

Irreversible inhibitors

- two-step inhibition: 1) requires initial reversible binding followed by 2) covalent interaction, which increases target selectivity
- Greater ligand efficiency provides high selectivity and potency without jeopardizing pharmaceutical properties



Deep Target Inactivation

Irreversible inhibitors

- can cause permanent inactivation of bound protein
- can drive target elimination through normal cellular degradation processes
- can trigger rapid apoptosis or differentiation into normal, mature cells



Greater Therapeutic Window

Irreversible inhibitors

- are designed to maintain an effect without sustained systemic exposure, unlike conventional reversible drugs, which typically need to be present to provide benefit
- Uncoupling of drug effects from drug exposure can potentially enable lower drug dosing or less frequent dosing regimens vs. reversible approaches




Benefits of Covalent Irreversible Inhibition

Irreversible inhibitors facilitate prolonged target occupancy effect, without prolonged systemic exposure

Example: Ibrutinib, an Irreversible Inhibitor with Long Kinetic Half Life and Short Biologic Half Life


(Im/gn)



- Ibrutinib has a short biologic half life of ~4-6 hrs but prolonged receptor occupancy
- Ibrutinib rapidly achieved high receptor occupancy, sustained for over 24 hours, without constant systemic exposure
- Reversible inhibitors often require constant systemic exposure to maintain occupancy and reach IC₉₀, thereby potentially limiting tolerability



Our Technology Platform – Irreversible Inhibitors



10


🔊 biomea

Biomea Pipeline – Pursuing Up to 7 Tumor Types and Diabetes in the Clinic in 2022

	Program	Discovery X IND Enabling X Phase 1 X Phase 2 X Phase 3	Target Population (US Incidence)	Key Milestone
		MLL-R & NPM1 Liquid Tumors (AML, ALL)	2.5K 7.5K MLL-r NPM1	Patient enrollment
Menin Programs	BMF-219 (Oncology)	Additional Liquid Tumors (MM, DLBCL)	~18K ~35K DLBCL MM	Patient enrollment
		KRAS Solid Tumors (Lung, Pancreatic, CRC)	~60K ~60K ~70K Lung Panc. CRC (KRA5) (RA5) (RA5)	IND filing
	Menin Inhibition (Metabolic)	Diabetes Mellitus (Type 2, Type 1)	1.6M 25.3M Type 1 Type 2	Preclinical data presentation at an upcoming meeting
Additional Oncology Programs	Target #2	Oncology	N/A Undisclosed	Lead candidate and target announcement
\bigcirc	Target #3	Oncology	N/A Undisclosed	Update on progress in 2022

BMF-219 to Pursue Multiple Tumor Types in 2022

Target Patient Population for BMF-219



Sources: Journović, K. K., Roche-Lestienne, C., Ghobriol, I. M., Focon, T., Quesnel, B., & Manier, S. (2018). Targeting MTC in multiple myeloma. Leukemia, 32(6): 1255–1305. https://doi.org/10.1038/s41375-018-0036-x Rodel, P., & Smith, S. M. (2018). Double hit and double expresses in Jmphane Definition and reastment. Cancer, 124(24): 4252. https://doi.org/10.1038/s41375-018-0036-x Rodel, P., & Smith, S. M. (2018). Double hit and double expresses in Jmphane Definition and reastment. Cancer, 124(24). 4252. https://doi.org/10.1038/s41375-018-0036-x Rodel, P. (2018). Double hit and double expresses in Jmphane Definition and reastment. Cancer, 124(24). 4252. https://doi.org/10.1038/s41375-018-0036-x Rodel, P. (2019). Rodel, S. (2019). Rodel, S. (2019). Rodel, Rodel, Rodel, Rodel, Rodel, S. (2019). Rodel, S. (2019). Rodel, Rodel, S. (2019). Rodel, Rod



BMF-219 – Novel Irreversible Covalent Inhibitor of Menin

Pipeline-in-a-Pill – Single Agent for Multiple Indications



Strong Pathway Control

Large effect on target genes and proteins leading to cell death

Multiple Shots on Goal



Consistent On-Target Effect





💭 Wide Safety Margin



BMF-219 Shown to Inhibit A Complex Interaction Independent of the MLL Fusion Partner

Role of Menin-MLL Complex





Menin-MLL Fusions


Different fusions result in different binding affinities between MLL fusion proteins and Menin

MLL Fusions (AML/ALL)	Prevalence (%)
AF4	36%
AF9	19%
ENL	13%
AF10	8%
ELL	4%
PTD	4%
80+ additional fusions	16%

Source: Meyer, C. et al. (2017). The MLL recombinome of acute leukemias in 2017. Leukemia, 32(2), 273–284.




BMF-219 Demonstrated Rapid and Near Complete Reduction of Expression of Oncogenes



- Irreversible inhibitor, BMF-219, downregulates expression of N
 - downregulates expression of Menin (via the target *MEN1* gene) and critical leukemogenic genes (e.g. *MEIS1* and *HOXA9*)
 - *MEIS1* is a gene that can be an accelerator of leukemic transformation (along with *HOXA9*)
 - HOXA9 is a gene involved in myeloid differentiation and can be leukemogenic
 - DNMT3A is a gene that codes for a methyltransferase, which can be leukemogenic when mutated
 - BMF-219 demonstrated up to 80% reduction in readout genes by 6 hours and approximately 90%+ reduction at 24 hours



BMF-219 Displayed Superior Impact on Key Gene Signatures in MLL-rearranged AML Cell Line



- BCL2 expression was reduced <u>~20 to 30-fold</u> at 24 hrs post-treatment with BMF-219 and remained largely unaltered at 6 hrs post-treatment with BMF-219
- HOXA9 expression was reduced ~15-fold at 24 hrs post treatment with BMF-219
- MYC expression was reduced ~100-200 fold at 6 hrs and 24 hrs post-treatment with BMF-219

BMF-219 – Novel Irreversible Covalent Inhibitor of Menin

Pipeline-in-a-Pill – Single Agent for Multiple Indications



Strong Pathway Control



Multiple Shots on Goal

Acute leukemias, MYC addicted and driven cancers, RAS/RAF driven solid tumors




Consistent On-Target Effect




Wide Safety Margin



BMF-219 Has the Potential to Impact Important Binding Partners Involved in Multiple Tumors



Resulting change of function of menin impacts important binding partners involved in oncogenesis




BMF-219 has the potential to address additional patient populations that are dependent on menin or some of its binding partners



Acute Leukemia, DLBCL, MM, & Other Tumor Types Have High Menin Dependency Based on Broad Institute DEPMAP Dataset

BROAD Institute Cancer Dependency Map (DEPMAP) for Menin (*MEN1*)




Note: CERES MENIN Dependency scores less than -1 in various tumor types imply that menin is considered essential for cell survival in those tumor types

- Cell viability scores have shown that menin plays a key role in survival of multiple tumors
- **High menin dependency in liquid and solid tumors,** beyond acute leukemias, provides rationale for further analysis in dependent tumor types
- Biomea is exploring the potential for irreversible inhibition of menin in a variety of liquid and solid tumor types




BMF-219 Shown to Disrupt MYC Genomic Function via Broad Impact on the Complexes Surrounding Menin

Irreversible Covalent Menin Inhibitor – BMF-219



TF activity inference using ChIP-seq of differentially expressed genes in MOLM-13 cells incubated with 500 nM BMF-219 at 24 hours. Each bar represents a study in the GEO repository using the specified TF antibody.

- In MOLM-13 cells treated with BMF-219, the top transcription factors regulating gene expression are MYC and MAX
- IRF4, MYC, and MAX are known drivers for some forms of DLBCL, (addicted) multiple myeloma, and multiple additional tumors



Reversible Menin Inhibitor – SNDX-50469


• Significantly less impact on MYC expression (2x fold) and genomic function by clinical reversible menin inhibitor

 In contrast, BMF-219 treatment led to a ~100-200x reduction in MYC expression at 24 hours



MYC is constitutively and aberrantly expressed in over 70% of human cancers

MYC transcriptional complex facilitates expression of oncogenesis via MYC target genes



Source: Madden et al., Molecular Cancer volume 20, Article number: 3 (2021); Martimez-Martín et al. Cancer Drug Resist 2021;4:842-65; Xia Y. et al., Acta Haematol 2020;143:520–528; Zhu L., et al. (2017).. Nat. Commun. 8, 15278.; Musti et al., Oncogene . 2002 Sep 19;21(42):6434-45.

Multiple Myeloma (MM)

- MYC addiction increases with stage and line of therapy
- ~20-50% MYC dysregulation or translocations in newly
- diagnosed MM patients
- ~50-70% of advanced r/r MM patients have MYC dysregulation

KRAS Mutant Solid Tumors

- Menin regulates downstream pathways associated with KRAS signaling, including MYC, MAPK/ERK, and JunD
- ~30% of newly diagnosed NSCLC have a KRAS mutation
- ~97% of pancreatic cancer patients have a RAS mutation
- ~45% of CRC patients have a RAS mutation

Diffuse Large B-Cell Lymphoma (DLBCL)

- Double and Triple Hit and Double expressors (BCL2 and MYC overexpression) DLBCL represents ~40% of patients
- >50% of relapsed/refractory DLBCL are double expressors

Sources: Jovanović, K. K., Roche-Lestienne, C., Ghobriol, I. M., Facon, T., Quesnel, B., & Manier, S. (2018). Targeting MYC in multiple myeloma. Leukemia, 32(6), 1295–1306. https://doi.org/10.1038/s41375-018-0036-x ; Riedell, P. A., & Smith, S. M. (2018). Double hit and double expressors in lymphomo: Definition and treatment. Cancer, 124(24), 4622–4632. <u>https://doi.org/10.1002/cncr.31646</u>; Kempf, E., Rousseau, B., Besse, B., & Paz-Ares, L. (2016). KRAS oncogene in lang cancer: focus on molecularly driven clinical trials. European respiratory review : an official Journal of the European Respiratory Society, 25(139), 71–76. https://doi.org/10.1183/16000617.0071-2015; Lanfredini, S., Thapa, A., & Notilli, E. (2019). RSA in pancreatic concer. Biochemicol Society transcitorin. 47(4), 961–972. <u>https://doi.org/10.1042/SES201202521</u>; SernaeBlasco, R., Sanz-Alvarez, M., Aguilera, Ó., & García-Foncillas, J. (2019). Targeting the RAS-dependent chemoresistance: The Warburg connection. Seminars in cancer biology, 54, 80–90. https://doi.org/10.1016/j.semcancer.2018.01.016



BMF-219 – Novel Irreversible Covalent Inhibitor of Menin

Pipeline-in-a-Pill – Single Agent for Multiple Indications



Strong Pathway Control



Multiple Shots on Goal



Consistent On-Target Effect


Pathway control and cell killing seen at same predicted dose across indications




Wide Safety Margin



BMF-219 Exerted Superior Cell Killing of AML Cell Lines at Half the Dose




- BMF-219 killed >90% of AML cells in MLL-rearranged and NPM1 mutant cell lines at 4 days post-treatment
- Reversible menin inhibitors generally report significantly less cell killing of AML cell lines as a single agent



23


BMF-219 Produced Near Complete Inhibition of Growth at 0.560µM Across Acute Leukemia Cell Lines



BMF-219 demonstrated rapid shut down of metabolic activity, sustained over the 14-day study duration
 BMF-219 responses were superior to a tested reversible menin inhibitor (MI-503) with respect to both onset and durability of metabolic suppression



BMF-219 Produced Near Complete Inhibition of Growth at 0.560µM in Multiple Myeloma and KRAS Solid Tumor Cell Lines



Impairment of survival in multiple myeloma model (KMS-20 cell line, 0.56 μ M doses) by irreversible menin inhibitor BMF-219

KRAS Pancreatic Cancer Viability (MIA-PaCa--2 cells, 0.560µM) 3000000 2000000 1000000 0 0 Day 4 Day 7 Day 11

-DMSO -


Impairment of survival in G12C KRAS mutation driven pancreatic cancer model (MIA-PaCa-2, 0.56µM doses) by irreversible menin inhibitor BMF-219 versus a reversible menin inhibitor (MI-503)

-MI-503

BMF-219




BMF-219 Produced Near Complete Inhibition of Growth at $1\mu M$ in AML ex-vivo Samples



Growth Inhibition of ex-vivo AML Cells from Patients (1µM Exposure)



BMF-219 Produced Near Complete Inhibition of Growth at 1μ M in **DLBCL Cell Lines**



BMF-219 Growth Inhibition in DLBCL Cell Lines, ASH 2021

- · Irreversible menin inhibition by BMF-219 led to marked growth inhibition in multiple DLBCL cell lines
- We believe this is due to disruption of Menin-MYC
- One of the clinical stage reversible menin inhibitors tested displayed activity, but at 5-10x higher concentration
- The other clinical reversible inhibitor did not achieve IC50 in the tested cell lines at any concentration tested

🕥 biomea 27

BMF-219 – Novel Irreversible Covalent Inhibitor of Menin

Pipeline-in-a-Pill – Single Agent for Multiple Indications



Strong Pathway Control



Multiple Shots on Goal



Consistent On-Target Effect



Wide Safety Margin Strong preclinical safety profile from animal studies



BMF-219 Was Highly Selective in Key Screening and Safety Panels

No Histopathology Findings Were Observed with BMF-219 in GLP and non-GLP Toxicology Studies


Kinase screening

- 169 kinases screened; only two wild type kinases showed greater than 50% inhibition upon treatment with BMF-219
- In-house analysis of menin revealed no relevant structural similarity between targeted binding pocket and tyrosine kinases with known involvement in hematological cancers

Oncopanel screening


- Minimal impact of BMF-219 treatment on cell metabolism in leukemia and lymphoma cell lines that have wild type MLL, but no menin-linked mechanism for disease
- Findings are consistent with external studies, showing that menin-MLL interaction is not generally cellessential and only critical to survival in those cells that contain aberrant biology

Glutathione reactivity



- Drugs with limited non-specific interactions have long half-lives
- BMF-219 had less reactivity than the approved irreversible drugs omeprazole and neratinib based on the results from the study


Safety screen Metabolic Activity (%) BMF-219 Vehick



- BMF-219 was also profiled on the **SafetyScreen44** panel (CEREP/Eurofins Discovery), an *in-vitro* panel of 44 common selected targets to identify significant off-target interactions
- Findings showed no meaningful impact (greater than 50% activation or inhibition) of BMF-219 across these key safety assays



BMF-219 Achieved Significant Survival Benefit in A Disseminated Leukemia Xenograft Model




- Mice were inoculated with xenograft cancer cells at high levels (1x10⁷ MV4;11-luc) with greater than 90% viability
- BMF-219 treatment showed notable reduction in tumor burden and survival benefit over vehicle control (72% at 20mg/kg and 94% at 40mg/kg)
- Daily dosing for 14 days was well-tolerated and caused minimal body weight changes

BMF-219: Next Generation Irreversible Covalent Menin Inhibitor

BMF-219: A Molecule That Really Grabs You and Won't Let Go

BMF-219 Properties	
Molecular Weight Approximately 500 kD	\sim
Nanomolar Potency in Key Targeted Cell Lines:	
MLL-r	\sim
NPM1 FLT3-ITD	\sim
DLBCL MYC Driven Tumors	\sim
ММ	\sim
KRAS Mutants (pan mutation)	\sim
hERG inhibition ~5% at 10 μM	\sim
Significant Downregulation of HOXA9, MEN1, and MYC	\sim
No Histopath Findings in IND Enabling Tox Studies	\sim

Predicted Efficacious Human AUC for BMF-219



Next Generation Menin Inhibitor

Attacks the target by forming a covalent bond (irreversible inhibitor)


Challenges of 1 st Gen Menin Inhibitors	Solutions Offered by BMF-219
Poor PK/PD Properties (Inefficient Pharmacology)	Efficient Pharmacology (Target AUC/Daily Exposure) Leading to Wider Therapeutic Window
Limited impact on Key Gene Signaling (<i>MEN1, HOXA9, MYC</i>) at Clinically Achievable Dose Levels	Significant Impact on MEN1, HOXA9, and MYC
Focused on Menin-MLL Disruption For AML/ALL	Broad Tumor Type Impact via MYC Inhibition (ALL, AML, DLBCL, MM, RAS activated Solid Tumors)
Poor impact on Cell Viability in Key Leukemia Sub-Types	Deep Tumor Impact Across Multiple Tumor Types (ALL, AML, DLBCL, MM, RAS activated Solid Tumors)
Dose Limiting Cardiac Toxicity	Minimum Impact on hERG at 10uM (at ≥10x the Targeted Clinical Dose Level)
Single Agent CR Rate @ 6-month ~10%	TBD - Currently Enrolling Patients

Complete Remission (CR) is defined as: Bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; ANC ≥1.0 X 10⁹/L (1,000/µL); platelet count ≥100 X 10⁹/L (100,000/µL)

BMF-219 Phase I Study in r/r Acute Leukemia Patients

Phase I first-in-human dose-escalation and dose-expansion study of BMF-219 enrolling adult patients with acute leukemia, including those with an MLL/KMT2A gene rearrangement or NPM1 mutation

Phase I Study Design



Abbreviations: ALL Acute Lymphoblastic Leukemia AML Acute Myeloid Leukemia AMPL Acute Mixed Phenotype Leukemia CRR Complete Response Rate CYP3A4 Cytochrome 450 3A4 DLT Dose Limiting Toxicity FIH First-inhuman KMT2A Lysine Methyltransferase 2A MLL Mixed Lineage Leukemia MLLr Mixed Lineage Leukemia-rearranged NPM1 Nucleophosmin 1 PO Administered by Mouth PK Pharmacokinetic R/R Relapsed/Refractory RP2D Recommended Phase 2 Dose TEAE Treatment Emergent Adverse Event




Clinical Study Plan – Enrolling up to 7 Tumor Types and Diabetic Patients in 2022


	Prog	gram	H1 2022	H2 2022					
	BMF-219 (Oncology)	AML / ALL (MLL-r, NPM1)	Trial Initiated in Q4 '21						
Menin Programs		DLBCL (DHL / DEL)	Ph I. Enrollment						
		MM (MYC driven)	Ph I. Filment						
		Lung, Pancreatic, CRC (KRAS Mut.)	Bits Data	IND Filing Filing Initiation					
	Menin Inhibition (Metabolic)	Diabetes (T1D/T2D)	Bissi Preclinical Data	Filing IND Ph. I Trial Initiation					

Potential for Menin Inhibition Demonstrated by Beta Cell Ablation Diabetes Model in MEN1 Excised Mice

MEN1 Excision Prevents Development of Streptozotocin (STZ)-induced Hyperglycemia



Multiple low-dose streptozotocin (MLD-STZ) administered to the control and *Men1*-excised mice to induce beta cell damage and a diabetes-like environment



Men1-excised mice did not develop hyperglycemia in STZ model, which was observed in the control group

Sources: Yang et al. (2010) Deletion of the Men1Gene Prevents Streptozotocin-Induced Hyperglycemia in Mice. Experimental Diabetes Research, 2010, 1–11. doi:10.1155/2010/876701




BMF-219 Ameliorated Diabetes in Animal Models



Experiments

BMF-219 was able to normalize glucose levels in the majority of animals after just two weeks of treatment. The majority of the effect was maintained despite complete washout of BMF-219

Preclinical data support BMF-219 as an oral, long-acting treatment for diabetes



 Model works to decrease beta cell counts and induce insulin resistance in male rats
 While males develop diabetes,

Female rats do not develop diabetes,



- Model inhibits production of insulin by beta cells in addition to inducing beta cell death
 - High dose models lead to rapid ablation of beta cells and hyperglycemia while low dose models lead to less pronounced reduction in beta cells and insulin secretion



Engage with the FDA in Q1 2022 and File IND by H2 2022

Conduct Additional Translational Work

Submit Data for 2022 Conference Publication

Sources: King, A. J. (2012). The use of animal models in diabetes research. British Journal of Pharmacology, 166(3), 877–894; Willcox, A., Richardson, S. J., Bone, A. J., Foulis, A. K., & Morgan, N. G. (2010). Evidence of increased islet cell proliferation in patients with recent-onset type 1 diabetes. Diabetologia, 53(9), 2020–2028.



Biomea Fusion – WE AIM TO CURE

\leq
\checkmark
\checkmark
\square
\square

Established FUSION platform technology for discovery of irreversible covalent inhibitors

- Lead molecule (BMF-219) with best-in-class potential and favorable safety profile
- Initiate studies with BMF-219 in up to 7 tumor types (liquid and solid) in 2022
- Significant addressable market and scarcity of effective treatment options for clinically targeted tumor types
 - IND enabling work in progress for diabetic patients
 - **Capitalized into 2024**

Near Term Milestones – Biomea Fusion (NASDAQ: BMEA)

BMF-21	9 – Liquid Tumors	
	IND Clearance	Completed
\$ \$	DLBCL Preclinical ASH 2021 Abstract	Completed
ŗî	Enrolling Phase I Study in AML/ALL	In Progress
100 100 100 100 100 100 100 100 100 100	Additional Preclinical Data in DLBCL/MM	H1 2022
L Î	BMF-219 Phase I DLBCL/MM Trial Initiation	H1 2022
DME 21	9 – Solid Tumors	
DIVIT-21	9 - Solia Tulliors	
101 8888	Additional Preclinical Data in KRAS Mutant Tumors	H1 2022
P	IND Filing	H2 2022
<u>r</u>	BMF-219 Phase I KRAS Mutant Trial Initiation (Pancreatic, Lung, Colorectal)	Q4 2022

Menin Inh. – Diabetes

	Diabetes Menin Pathway Validation	H1 2022
	IND Filing	H2 2022
<u></u> ří	Phase I Diabetes Trial Initiation	H2 2022
Additio	onal Programs	
Additio	onal Programs	
Additio	onal Programs 2 nd Pipeline Candidate Announced	H1 2022



Company Financials

Detailed Financials (unaudited)

Three Months Ended September 30,				Nine Months Ended September 30,			
2021		2020		2021		2020	
\$	7,886	\$	789	\$	16,908	\$	1,339
\$	4,752	\$	346	\$	10,022	\$	489
\$	12,638	\$	1,135	\$	26,930	\$	1,828
\$	(12,638)	\$	(1,135)	\$	(26,930)	\$	(1,828)
\$	32		_	\$	73	\$	2
\$	(12,606)	\$	(1,135)	\$	(26,857)	\$	(1,826)
	-		_	\$	2		_
\$	(12,606)	\$	(1,135)	\$	(26,855)	\$	(1,826)
\$	(0.43)	\$	(0.10)	\$	(1.21)	\$	(0.18)
29	9,001,213	11,	,724,100	2	2,105,321	10	,082,667
	202 \$ \$ \$ \$ \$ \$ \$ \$ \$	September 2021 \$ 7,886 \$ 4,752 \$ 12,638 \$ (12,638) \$ 32 \$ (12,606)	September 30, 2021 2020 \$ 7,886 \$ \$ 4,752 \$ \$ 12,638 \$ \$ (12,638) \$ \$ 32 \$ \$ (12,606) \$ \$ (12,606) \$ \$ (12,606) \$ \$ (12,606) \$ \$ (12,606) \$ \$ (0,43) \$	September 30, 2021 2020 \$ 7,886 \$ 789 \$ 4,752 \$ 346 \$ 12,638 \$ 1,135 \$ (12,638) \$ (1,135) \$ 32 — \$ (12,606) \$ (1,135) \$ (12,606) \$ (1,135) \$ (12,606) \$ (1,135) \$ (12,606) \$ (1,135)	September 30, 2021 2020 2020 \$ 7,886 \$ 789 \$ \$ 12,638 \$ 1,135 \$ \$ 12,638 \$ 1,135 \$ \$ (12,606) \$ (1,135) \$ \$ (12,606) \$ (1,135) \$ \$ (12,606) \$ (1,135) \$ \$ (12,606) \$ (1,135) \$ \$ (12,606) \$ (1,135) \$ \$ (12,606) \$ (1,135) \$ \$ (12,606) \$ (1,135) \$ \$ (0,43) \$ (0,10) \$	September 30, September 2021 2020 2021 \$ 7,886 \$ 789 \$ 16,908 \$ 4,752 \$ 346 \$ 10,022 \$ 12,638 \$ 1,135 \$ 26,930 \$ (12,638) \$ (1,135) \$ (26,930) \$ 32 - \$ 73 \$ (12,606) \$ (1,135) \$ (26,857) - - \$ 2 \$ (12,606) \$ (1,135) \$ (26,855) \$ (0,43) \$ (0,10) \$ (1.21)	September 30, September 30, 2021 2020 2021 2020 \$ 7,886 \$ 789 \$ 16,908 \$ \$ 4,752 \$ 346 \$ 10,022 \$ \$ 12,638 \$ 1,135 \$ 26,930 \$ \$ 12,638 \$ 1,135 \$ 26,930 \$ \$ 12,638 \$ (1,135) \$ (26,930) \$ \$ 32 - \$ 73 \$ \$ (12,606) \$ (1,135) \$ (26,857) \$ - - \$ 2 - - - \$ 2 \$ \$ (12,606) \$ (1,135) \$ (26,857) \$ \$ (12,606) \$ (1,135) \$ (26,855) \$ \$ (0.43) \$ (0.10) \$ (1.21) \$



